Perspective Therapeutics (NYSE:CATX) Research Coverage Started at Bank of America

Bank of America assumed coverage on shares of Perspective Therapeutics (NYSE:CATX) in a research note released on Thursday, Marketbeat.com reports. The brokerage issued a buy rating and a $24.00 target price on the stock.

A number of other equities research analysts have also recently weighed in on the company. Cantor Fitzgerald reiterated an overweight rating on shares of Perspective Therapeutics in a research note on Tuesday, June 25th. B. Riley upped their price target on Perspective Therapeutics from $12.00 to $17.00 and gave the stock a buy rating in a research note on Tuesday, April 9th. Oppenheimer restated an outperform rating on shares of Perspective Therapeutics in a research note on Tuesday, June 18th. Royal Bank of Canada restated an outperform rating and set a $30.00 price target on shares of Perspective Therapeutics in a research note on Friday, June 14th. Finally, Lifesci Capital restated an outperform rating on shares of Perspective Therapeutics in a research note on Monday, May 6th. Seven research analysts have rated the stock with a buy rating, According to data from MarketBeat, Perspective Therapeutics presently has a consensus rating of Buy and a consensus price target of $20.00.

Perspective Therapeutics Trading Up 0.6 %

Shares of NYSE CATX opened at $13.70 on Thursday. The company has a debt-to-equity ratio of 0.01, a current ratio of 12.98 and a quick ratio of 12.98. Perspective Therapeutics has a twelve month low of $2.05 and a twelve month high of $19.05. The company has a 50 day moving average price of $12.40.

Perspective Therapeutics (NYSE:CATX) last issued its quarterly earnings data on Wednesday, May 15th. The company reported ($0.20) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.10. The firm had revenue of $0.33 million during the quarter. On average, equities research analysts forecast that Perspective Therapeutics will post -1 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Perspective Therapeutics news, CEO Johan M. Spoor acquired 10,000 shares of the company’s stock in a transaction that occurred on Thursday, June 13th. The shares were purchased at an average price of $11.70 per share, with a total value of $117,000.00. Following the completion of the acquisition, the chief executive officer now directly owns 13,757 shares of the company’s stock, valued at approximately $160,956.90. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In other Perspective Therapeutics news, Director Robert F. Williamson III acquired 3,003 shares of the company’s stock in a transaction that occurred on Wednesday, May 29th. The shares were purchased at an average price of $13.30 per share, with a total value of $39,939.90. Following the completion of the acquisition, the director now directly owns 36,879 shares of the company’s stock, valued at approximately $490,490.70. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Johan M. Spoor acquired 10,000 shares of the company’s stock in a transaction that occurred on Thursday, June 13th. The shares were acquired at an average cost of $11.70 per share, for a total transaction of $117,000.00. Following the acquisition, the chief executive officer now directly owns 13,757 shares of the company’s stock, valued at $160,956.90. The disclosure for this purchase can be found here. Insiders have acquired 30,814 shares of company stock valued at $385,487 over the last quarter. Company insiders own 3.52% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of CATX. Simplicity Wealth LLC acquired a new position in Perspective Therapeutics during the first quarter worth $40,000. ZWJ Investment Counsel Inc. acquired a new stake in Perspective Therapeutics in the first quarter valued at $26,000. RIA Advisory Group LLC grew its holdings in Perspective Therapeutics by 1,313.4% in the first quarter. RIA Advisory Group LLC now owns 106,853 shares of the company’s stock valued at $127,000 after purchasing an additional 99,293 shares during the last quarter. Bleakley Financial Group LLC acquired a new stake in Perspective Therapeutics in the first quarter valued at $40,000. Finally, Vanguard Group Inc. grew its holdings in Perspective Therapeutics by 34.6% in the first quarter. Vanguard Group Inc. now owns 17,780,106 shares of the company’s stock valued at $21,158,000 after purchasing an additional 4,566,356 shares during the last quarter. Institutional investors and hedge funds own 54.66% of the company’s stock.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.